Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 11 (April 10), 2008: pp. 1906-a
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2008.16.2230
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Singh, N. K.
Right arrow Articles by Sangwan, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, N. K.
Right arrow Articles by Sangwan, G.
Related Articles
Right arrowRelated Reply
Right arrowRelated Article

CORRESPONDENCE

Low Platelet Counts in Cancer Patients: Should Heparin for Venous Thromboembolism Prophylaxis Be Instituted?

Nishith K. Singh, Gaurav Sangwan

Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL

To the Editor:

Dr Lyman and colleagues in the American Society of Clinical Oncology Guideline Recommendations for Prophylaxis of Venous Thromboembolism do not comment on the indications for heparin in patients with thrombocytopenia, which is common among patients with malignancy.1

We recently witnessed a hospitalized patient with acute leukemia and platelet levels of 18,000/mm3 who developed an acute upper extremity deep vein thrombus. Although in her case, it was clearly related to a peripherally inserted central catheter in the affected limb, we wonder if it demonstrates her being at a considerably high risk for spontaneous thromboembolic events. The treating team could not gather sufficient evidence to institute prophylactic dosage of heparin in view of her high presumed risk of bleeding. Two out of the three major randomized, double-blind, placebo-controlled trials on thromboembolism prophylaxis in hospitalized patients (the Prophylaxis in Medical Patients with Enoxaparin trial and the Prevention of Recurrent Venous Thromboembolism study), have specifically excluded patients with platelet counts less than 100,000/mm3.2,3 As such, evidence for thromboembolism prophylaxis in patients with platelet count less than 100,000/mm3 is probably not clear.

Should thrombocytopenia be a contraindication for heparin prophylaxis? At what level of the quantitative defect should prophylaxis be safely withheld? We seek authors' expert opinion on this matter of importance.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCES

1. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007[Abstract/Free Full Text]

2. Samama MM, Cohen AT, Darmon J-Y, et al: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341:793-800, 1999[Abstract/Free Full Text]

3. Leizorovicz A, Cohen AT, Turpie AG, et al: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874-879, 2004[Abstract/Free Full Text]


Related Reply

  • In Reply
    Alok A. Khorana, Charles W. Francis, Anna Falanga, and Gary H. Lyman
    JCO 2008 26: 1906-1907 [Full Text]

Related Article

  • American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
    Gary H. Lyman, Alok A. Khorana, Anna Falanga, Daniel Clarke-Pearson, Christopher Flowers, Mohammad Jahanzeb, Ajay Kakkar, Nicole M. Kuderer, Mark N. Levine, Howard Liebman, David Mendelson, Gary Raskob, Mark R. Somerfield, Paul Thodiyil, David Trent, and Charles W. Francis
    JCO 2007 25: 5490-5505 [Abstract] [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Singh, N. K.
Right arrow Articles by Sangwan, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, N. K.
Right arrow Articles by Sangwan, G.
Related Articles
Right arrowRelated Reply
Right arrowRelated Article
About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online